Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection

Randy M Stalter, Jared M Baeten, Deborah Donnell, Matthew A Spinelli, David V Glidden, Warren C Rodrigues, Guohong Wang, Michael Vincent, Nelly Mugo, Andrew Mujugira, Mark Marzinke, Craig Hendrix, Monica Gandhi, Partners PrEP Study Team, Connie Celum, Jared M Baeten, Deborah Donnell, Robert W Coombs, Jairam R Lingappa, M Juliana McElrath, Kenneth H Fife, Edwin Were, Elioda Tumwesigye, Patrick Ndase, Elly Katabira, Elly Katabira, Allan Ronald, Elizabeth Bukusi, Craig R Cohen, Jonathan Wangisi, James D Campbell, Jordan W Tappero, James Kiarie, Carey Farquhar, Grace John-Stewart, Nelly R Mugo, Kenneth Ngure, James D Campbell, Jordan W Tappero, Jonathan Wangisi, Randy M Stalter, Jared M Baeten, Deborah Donnell, Matthew A Spinelli, David V Glidden, Warren C Rodrigues, Guohong Wang, Michael Vincent, Nelly Mugo, Andrew Mujugira, Mark Marzinke, Craig Hendrix, Monica Gandhi, Partners PrEP Study Team, Connie Celum, Jared M Baeten, Deborah Donnell, Robert W Coombs, Jairam R Lingappa, M Juliana McElrath, Kenneth H Fife, Edwin Were, Elioda Tumwesigye, Patrick Ndase, Elly Katabira, Elly Katabira, Allan Ronald, Elizabeth Bukusi, Craig R Cohen, Jonathan Wangisi, James D Campbell, Jordan W Tappero, James Kiarie, Carey Farquhar, Grace John-Stewart, Nelly R Mugo, Kenneth Ngure, James D Campbell, Jordan W Tappero, Jonathan Wangisi

Abstract

New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.

Keywords: PrEP; ELISA; HIV prevention; immunoassay; urine.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

References

    1. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016; 30:1973–83.
    1. Yun K, Xu JJ, Zhang J, et al. Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV. Sex Transm Infect 2018; 94:163–8.
    1. Haberer JE Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS 2016; 11:10–7.
    1. Gandhi M, Wang G, King R, et al. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. AIDS 2019; 34:255–60.
    1. Baeten JM, Donnell D, Ndase P, et al. ; Partners PrEP Study Team Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410.
    1. Gandhi M, Bacchetti P, Spinelli MA, et al. Brief report: validation of a urine tenofovir immunoassay for adherence monitoring to PrEP and ART and establishing the cutoff for a point-of-care test. J Acquir Immune Defic Syndr 2019; 81:72–7.
    1. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014; 66:340–8.
    1. Drain PK, Kubiak RW, Siriprakaisil O, et al. Urine tenofovir concentrations correlate with plasma and relates to TDF adherence: a randomized directly-observed pharmacokinetic trial (TARGET Study). Clin Infect Dis 2019; 70:2143–51.
    1. Haaland RE, Martin A, Livermont T, et al. Urine emtricitabine and tenofovir concentrations provide markers of recent antiretroviral drug exposure among HIV-negative men who have sex with men. J Acquir Immune Defic Syndr 2019; 82:252–6.
    1. Koenig HC, Mounzer K, Daughtridge GW, et al. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Med 2017; 18:412–8.
    1. Hunt T, Lalley-Chareczko L, Daughtridge G, Swyryn M, Koenig H. Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP. AIDS Care 2019; 31:1203–6.
    1. Spinelli MA, Glidden DV, Rodrigues WC, et al. Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. AIDS 2019; 33:867–72.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere